<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673881</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-335-001</org_study_id>
    <nct_id>NCT00673881</nct_id>
  </id_info>
  <brief_title>ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study</brief_title>
  <official_title>ABT-335 (Choline Fenofibrate)Reverse Cholesterol Transport (RCT) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiant Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radiant Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study are:

        1. To evaluate the effect of ABT-335 (choline fenofibrate) on several parameters of RCT
           (reverse cholesterol transport) in men and post-menopausal women diagnosed with
           dyslipidemia (i.e., low high-density lipoprotein [HDL] cholesterol levels and elevated
           triglyceride [TG] concentrations).

        2. To evaluate longitudinal changes in several parameters of RCT in subjects with low HDL.

        3. To obtain pilot data for power calculations for subsequent comparative study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial assesses the effects of ABT-335 on RCT as measured by cholesterol efflux or rate
      of appearance of cholesterol (Ra in mg/kg/hr), cholesterol excretion (%/day), RCT efflux
      (mg/kg/day) and de novo cholesterol synthesis (%) during a baseline period (7 days) and
      during a treatment period (94 days).

      The goal of using RCT to reverse atherosclerosis is to increase the rate of cholesterol
      export or &quot;efflux&quot; from the tissues and plaques. An increase in this cholesterol efflux rate
      should shrink arterial plaques by decreasing their static accumulation of cholesterol. While
      some currently marketed drugs have a positive impact on RCT by increasing the rate of
      cholesterol excretion from the body, no drug has yet been approved to increase the rate of
      cholesterol efflux from the tissues
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Calculated Low Density Lipoprotein Cholesterol</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>Mean change in calculated LDL, baseline (average Day 0, 1 10) to end-of-treatment (12 weeks treatment,average Day 95)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Plasma Triglycerides</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>Change in plasma triglyceride, baseline (average Day 0, 1 10) to end-of-treatment (12 weeks treatment,Day 95)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in High Density Lipoprotein Cholesterol</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Mean change in plasma high density plasma lipoprotein cholesterol (HDL-C)baseline (average Day 0, 1 10) to end-of-treatment (12 weeks treatment,Day 95)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean Change in total cholesterol from baseline to End-of-treatment (Day 95)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Cholesterol Efflux</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in efflux rate from baseline to end-of-treatment. The efflux rate of cholesterol from peripheral tissues into the plasma was measured as mg/kg/hr. An IV infusion of [13C2] cholesterol mixed in 10% Intralipid® or Liposyn® and 10 % ethanol was given piggy-backed into normal saline over 24 hours. This was used to determine rate of appearance (Ra) cholesterol, measured by dilution of infused [13C2] cholesterol during the plateau phase of plasma enrichment (approximately the last 4 hours of the infusion), as well as to provide the plasma cholesterol traced into biliary sterols.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Cholesterol Ester Fractional Catabolic Rate (FCR)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change in FCR from baseline to end-of-treatment (12 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in de Novo Cholesterol Synthesis</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Plasma DNC was measured three times from blood draws on the 3 visits in the 10 day period following the isotope infusion at baseline and again at end-of-treatment at 12 weeks, and expressed in percent. Change from baseline to end-of-treatment expressed as percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neutral Sterol Excretion</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>The excretion rate of fecal neutral and acidic sterols was measured as mg/day, for each individual three times during the 10 day period following the isotope infusions at baseline and end-of-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bile Acid Excretion</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change in bile acid excretion from baseline to end-of-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutral Sterol Endogenous Excretion</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in neutral sterol endogenous excretion from baseline to end-of-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous Bile Acid Excretion</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in endogenous bile acid excretion from baseline to end-of-treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Abt-335</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-335 (choline fenofibrate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>choline fenofibrate</intervention_name>
    <description>135 mg choline fenofibrate daily(oral, capsule)</description>
    <arm_group_label>Abt-335</arm_group_label>
    <other_name>ABT-335</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male, non-smoker, 21 - 75 years of age inclusive.

          2. Female, non-smoker, 40 - 75 years of age inclusive.

          3. Post-menopausal women, as defined by lack of menses for at least 2 years and age &gt; 55,
             OR history of documented bilateral surgical oophorectomy, confirmed with an elevated
             follicle-stimulating hormone (FSH) at screening.

          4. HDL concentration (≤ 50 mg/dl women, ≤ 40mg/dl men)

          5. TG concentration 150-500 mg/dl, inclusive

          6. Ability to give informed consent

        Exclusion Criteria:

          1. Subject has history of diabetes mellitus, active hepatitis, gall bladder disease,
             gastric bypass surgery, or clinically significant abnormalities on screening
             (prestudy) physical examination or laboratory tests.

          2. Screening laboratory tests with hematocrit &lt;30%, aspartate aminotransferase
             (AST)/alanine aminotransferase (ALT) &gt; 2X upper limit of normal, abnormal
             thyroid-stimulating hormone (TSH), fasting glucose ≥126 mg/dl.

          3. Renal impairment with creatinine clearance &lt; 80 ml/min.

          4. Treatment within the last 6 months with drugs known to alter lipid metabolism
             including beta blockers, thiazide diuretics, bile acid resins, ezetimibe, fibrates,
             niacin, and fish oils (see Appendix 1). Washout of fibrates is not permitted.

          5. Treatment with drugs known to interact with ABT-335, e.g., warfarin (see Appendix 1).

          6. Treatment with HMG CoA reductase inhibitors (statins) within the past 4 weeks (see
             Appendix 1).

          7. History of allergy to egg or soy products.

          8. History of coronary heart disease (CHD), stroke or revascularization procedure in the
             six months prior to Visit 1.

          9. Current or recent history (past 12 months) of drug abuse or alcohol abuse. Alcohol
             abuse will be defined as &gt;14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5
             oz hard liquor).

         10. Participation in another clinical trial or exposure to any investigational agent
             within 30 days before visit 1.

         11. Individual has a condition the Principal Investigator believes would interfere with
             his/her ability to provide informed consent, comply with study instructions, or which
             might confound the interpretation of the study results or put the subject at undue
             risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Davidson, MD,FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research, 515 N State St, #2700</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <results_first_submitted>January 24, 2011</results_first_submitted>
  <results_first_submitted_qc>March 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 20, 2011</results_first_posted>
  <last_update_submitted>March 25, 2011</last_update_submitted>
  <last_update_submitted_qc>March 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Michael H. Davidson,MD, FACC</name_title>
    <organization>Radiant Research</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Choline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ABT 335</title>
          <description>choline fenofibrate, 135 mg/day,orally, 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ABT 335</title>
          <description>choline fenofibrate, 135 mg/day,orally, 12 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol (TC)</title>
          <description>Mean of fasting (&gt; 12 hours) total cholesterol measured at screening, Day 0, 1PM and Day 1, 1AM (Visit 1),Day 10 (Visit 4);23 values, per protocol population</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="221" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides (TG)</title>
          <description>Mean fasting (&gt; 12 hours) triglycerides measured at screening, Day 0, 1PM and Day 1, 1AM (Visit 1), Day 10 (Visit 4);23 values, per protocol population</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="241" spread="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High Density Lipoprotein Cholesterol (HDL)</title>
          <description>Mean fasting (&gt; 12 hours) HDL cholesterol measured at screening, Day 0, 1PM and Day 1, 1AM (Visit 1), Day 10 (Visit 4); 23 values, per protocol population</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low density lipoprotein cholesterol (LDL)</title>
          <description>Mean fasting (&gt; 12 hours) LDL cholesterol measured at screening, Day 0, 1PM and Day 1, 1AM (Visit 1), Day 10 (Visit 4); 23 values, per protocol population</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Calculated Low Density Lipoprotein Cholesterol</title>
        <description>Mean change in calculated LDL, baseline (average Day 0, 1 10) to end-of-treatment (12 weeks treatment,average Day 95)</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ABT 335</title>
            <description>choline fenofibrate, 135 mg/day,orally, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Calculated Low Density Lipoprotein Cholesterol</title>
          <description>Mean change in calculated LDL, baseline (average Day 0, 1 10) to end-of-treatment (12 weeks treatment,average Day 95)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.7" spread="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0042</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Plasma Triglycerides</title>
        <description>Change in plasma triglyceride, baseline (average Day 0, 1 10) to end-of-treatment (12 weeks treatment,Day 95)</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>ABT 335</title>
            <description>choline fenofibrate, 135 mg/day,orally, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Plasma Triglycerides</title>
          <description>Change in plasma triglyceride, baseline (average Day 0, 1 10) to end-of-treatment (12 weeks treatment,Day 95)</description>
          <population>per protocol</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-138.0" spread="150.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison baseline to end-of-treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in High Density Lipoprotein Cholesterol</title>
        <description>Mean change in plasma high density plasma lipoprotein cholesterol (HDL-C)baseline (average Day 0, 1 10) to end-of-treatment (12 weeks treatment,Day 95)</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ABT 335</title>
            <description>choline fenofibrate, 135 mg/day,orally, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in High Density Lipoprotein Cholesterol</title>
          <description>Mean change in plasma high density plasma lipoprotein cholesterol (HDL-C)baseline (average Day 0, 1 10) to end-of-treatment (12 weeks treatment,Day 95)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison from baseline to end-of-treatment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>NS</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cholesterol Efflux</title>
        <description>Change in efflux rate from baseline to end-of-treatment. The efflux rate of cholesterol from peripheral tissues into the plasma was measured as mg/kg/hr. An IV infusion of [13C2] cholesterol mixed in 10% Intralipid® or Liposyn® and 10 % ethanol was given piggy-backed into normal saline over 24 hours. This was used to determine rate of appearance (Ra) cholesterol, measured by dilution of infused [13C2] cholesterol during the plateau phase of plasma enrichment (approximately the last 4 hours of the infusion), as well as to provide the plasma cholesterol traced into biliary sterols.</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Cholesterol Ester Fractional Catabolic Rate (FCR)</title>
        <description>Change in FCR from baseline to end-of-treatment (12 weeks)</description>
        <time_frame>Baseline to 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in de Novo Cholesterol Synthesis</title>
        <description>Plasma DNC was measured three times from blood draws on the 3 visits in the 10 day period following the isotope infusion at baseline and again at end-of-treatment at 12 weeks, and expressed in percent. Change from baseline to end-of-treatment expressed as percent.</description>
        <time_frame>Baseline to 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Neutral Sterol Excretion</title>
        <description>The excretion rate of fecal neutral and acidic sterols was measured as mg/day, for each individual three times during the 10 day period following the isotope infusions at baseline and end-of-treatment.</description>
        <time_frame>baseline to 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bile Acid Excretion</title>
        <description>Change in bile acid excretion from baseline to end-of-treatment</description>
        <time_frame>Baseline to 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutral Sterol Endogenous Excretion</title>
        <description>Change in neutral sterol endogenous excretion from baseline to end-of-treatment</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endogenous Bile Acid Excretion</title>
        <description>Change in endogenous bile acid excretion from baseline to end-of-treatment</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Cholesterol</title>
        <description>Mean Change in total cholesterol from baseline to End-of-treatment (Day 95)</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ABT 335</title>
            <description>choline fenofibrate, 135 mg/day,orally, 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol</title>
          <description>Mean Change in total cholesterol from baseline to End-of-treatment (Day 95)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.0" spread="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>All adverse events occurring during the study are reported - the study included a treatment period, with pre-study baseline and post-study end-of-treatment procedures.</desc>
      <group_list>
        <group group_id="E1">
          <title>ABT 335</title>
          <description>choline fenofibrate, 135 mg/day,orally, 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael H. Davidson, MD FACC</name_or_title>
      <organization>Radiant Research</organization>
      <phone>312-494-2220 ext 2220</phone>
      <email>michaeldavidson@radiantresearch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

